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Abstract
Background and Aims
Deletions/mutations in the hepatitis B virus (HBV) pre-S region have been associated with
hepatocellular carcinoma (HCC). We aimed to study the evolutionary changes of pre-S
mutations prior to HCC development.
Methods
We studied the HBV pre-S sequences at 1 to 10 years preceding diagnosis of HCC in 74
patients with HBV-related HCC (HCC group). 148 chronic hepatitis B patients matched for
sex and age in 2:1 ratio, who had been followed up for at least 3 years without HCC (HCC-
free group) were recruited as controls. 56 and 47 patients of HCC and HCC-free groups
respectively had serially stored sera for longitudinally examination at 1–3 years, 4–6 years,
7–9 years and10 years prior to the recruitment of the study.
Results
Compared to the HCC-free group, higher frequencies of pre-S deletions and point mutations
(at 11 codons) were observed in the HCC group (p<0.05). Multiple logistic regression analysis
showed that pre-S deletions, point mutations at codon 51 and 167were independent factors asso-
ciated with HCC. Longitudinal observation showed that pre-S deletions andmost of the 11HCC-
associated pre-S point mutations existed at least 10 years before HCC development, and were
more prevalent preceding HCC development in patients fromHCC groups than HCC-free group.
The number of HCC-associated pre-S point mutations increased over time preceding HCC devel-
opment, and correlated positively with the time to HCC diagnosis (r = 0.220, p = 0.005).
Conclusions
High prevalence and cumulative evolution of pre-S mutations preceding HCC development
suggested a possible carcinogenic role of pre-S mutations and their potential application in
HCC risk prediction.
PLOS ONE | DOI:10.1371/journal.pone.0139478 September 30, 2015 1 / 14
OPEN ACCESS
Citation: Zhang A-Y, Lai C-L, Huang F-Y, Seto W-K,
Fung J, Wong DK-H, et al. (2015) Evolutionary
Changes of Hepatitis B Virus Pre-S Mutations Prior to
Development of Hepatocellular Carcinoma. PLoS
ONE 10(9): e0139478. doi:10.1371/journal.
pone.0139478
Editor: Ming-Lung Yu, Kaohsiung Medical University
Hospital, Kaohsiung Medical University, TAIWAN
Received: June 27, 2015
Accepted: September 14, 2015
Published: September 30, 2015
Copyright: © 2015 Zhang et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: The authors received no specific funding
for this work.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
Hepatocellular carcinoma (HCC) is the third major cause of cancer-related mortality in the
world, with an estimated annual death rate of 700,000 [1]. Hepatitis B virus (HBV) infection is
one of the major causes of HCC. Although the exact role of HBV in hepatocarcinogenesis is
not fully understood, several viral factors have been associated with a higher risk of HCC,
including viral load, HBV genotype, basal core promoter and precore mutations and pre-S
deletions [2, 3].
HBV pre-S region is located at 5’ end of the open reading frames of the surface gene and
consists of pre-S1 and pre-S2 domains. Pre-S region contains start codons for the expression of
large and middle HBV surface antigens (LHBs and MHBs, respectively), and promoter for the
expression of small HBV surface antigen (SHBs). It also contains both B- and T-cell epitopes
that mediate immune interactions, hepatocyte binding sites that participate in viral attachment,
and other functional domains (Fig 1) [4–9]. Thus, the pre-S region plays multiple and essential
roles in HBV replications, infections and viral-host interactions.
Naturally occurring pre-S mutations have been reported during the course of chronic hepa-
titis B (CHB) infection [10]. Chen et al. [6] compared the prevalence of pre-S deletions in vari-
ous stages of CHB infection and found that HCC patients have a higher frequency of pre-S
deletions. Recent case-control studies have demonstrated that HBV pre-S deletions are inde-
pendent factors associated with HCC development [11–13]. However, most studies were per-
formed using samples taken after the diagnosis of HCC. The association between pre-S
deletions detected prior to development of HCC and risk of HCC remains unclear. In addition,
apart from pre-S deletions, point mutations in the pre-S region which are often neglected in
most of the studies were also frequently observed in HCC patients [11, 13]. Moreover, there
were few studies that longitudinally investigated the evolution of pre-S mutations over the
period preceding HCC development.
In the present study, we investigated the association between pre-S mutations and the risk
of HCC development using a case-control approach. In addition, we investigated the preva-
lence and evolutionary changes of HBV pre-S mutations in up to 10 years prior to development
of HCC using a longitudinal approach.
Patients and Methods
Patients
From July 2007 to December 2012, we identified 116 CHB patients with clinical diagnosis of
HCC in our Liver Clinic, Queen Mary Hospital, The University of Hong Kong. Diagnosis of
HCC was made by following criteria: (1) positive histology or (2) increasing alpha-fetoprotein
(AFP) levels and positive imaging features by computed tomography or magnetic resonance
imaging. Of these 116 patients, 74 had stored sera available 1–3 years prior to the time of HCC
diagnosis and were enrolled in this study (HCC group). In addition, we enrolled 148 HCC-free
CHB patients who were age- and sex-matched to the 74 HCC patients in a 2:1 ratio for case-
control comparison (HCC-free group). For the HCC-free patients, all patients have been fol-
lowed up for at least 3 years after recruitment to exclude the possibility of subsequent HCC
development. Serum samples were collected and stored at -20°C until tested.
In addition, 56 of 74 HCC patients and 47 of 148 HCC-free control patients with serum
samples collected at earlier time points were longitudinal investigated. We studied the HBV
sequence in sera collected at 1–3 years, 4–6 years, 7–9 years and10 years prior to HCC devel-
opment and at the same time points for the HCC-free group. In the HCC group, a total of 164
serum samples from 56 HCC patients were examined, including 56 (34.2%) samples, 52
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(31.7%) samples, 35 (21.3%) and 21 (12.8%) samples at 4 time points of 1–3 years, 4–6 years,
7–9 years and10 years prior to diagnosis of HCC, respectively. In HCC-free group, 136
serum samples from 47 CHB patients were examined, including 47 (34.6) samples, 38 (27.9%)
samples, 34 (25%) samples and 17 (12.5%) samples at the same 4 corresponding time points,
respectively.
Fig 1. Mapping of pre-S mutations in HCC patients and HCC-free patients. The HBV pre-S region
contains immune epitopes and functional domains as depicted. The B-cell epitopes located at aa12-53,
aa72-78, aa94-117, aa120-143 and aa157-167 of pre-S gene (overlap regions merged); The T-cell epitopes
located at aa21-30, aa52-67, aa120-145 and aa163-172 of pre-S gene (overlap regions merged). The
functional domains include the start codons of pre-S1 (aa1) and pre-S2 (aa120), hepatocyte binding site (Hb,
aa21-47), S promoter (Sp, nt3045-3180), CCAAT box (nucleotide 3137–3141), topology domain (Topo)
includes heat shock protein 70 binding site (aa74-118) and cytosolic anchorage determinant (aa81-105),
nucleocapsid binding site (Nb, aa103-127), viral secretion domain (Vs, aa120-124), polymerized human
serum albumin binding site (pHSA, aa122-135), transactivator domain (Trans, aa21-90, 120–172). The
sequence of each sample is depicted as a block. The black blocks inside represent the deletions of amino
acids. The patient identifier numbers are listed at the right.
doi:10.1371/journal.pone.0139478.g001
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All patients were positive for the hepatitis B surface antigen (HBsAg) for more than 6
months. None was positive for antibody to the hepatitis C virus or had significant alcohol
intake. Patients were followed up in our clinic every 6 months for clinical assessment and mea-
surement of alpha-fetoprotein, liver biochemistry, and HBV serology. No written or oral con-
sent was obtained from the participants. The reason was that it was not an interventional study
and all data was analyzed anonymously. The study protocol conformed to the ethical guidelines
of the 1975 Declaration of Helsinki and was approved by the Institutional Review Board, the
University of Hong Kong and West Cluster of Hospital Authority, Hong Kong (Reference
Number: UW 14–360).
HBV DNA extraction, amplification and sequencing
HBV DNA was extracted from 200 μl of serum samples using the PureLink Genomic DNA kit
(Life Technologies, Carlsbad, CA) in accordance with manufacturer’s instructions. Semi-nested
polymerase chain reaction (PCR) was performed to amplify the entire HBV pre-S region with
two sets of nested primers. The outer primers were HBV 2747s (sense: 5’-GTTTACATA
CTCTGTGGAAGGC-3’ [nucleotide 2747–2767]) and HBV 255a (antisense: 5’-GAGTCTA
GACTCTGTGGTATT-3’ [nucleotide 255–235]), and inner primers were HBV 2814s (sense:
5’-GGGTCACCATATTCTTGGGAA-3’ [nucleotide 2814–2834]) and HBV 255a. All PCR
reactions were performed with the HotStarTaq Plus DNA Polymerase (Qiagen, Hilden, Ger-
many) in the GeneAmp PCR system 9700 (Applied Biosystems, Foster City, CA) according to
the previously described conditions [12]. PCR products were checked by electrophoresis in 1%
agarose gel.
The PCR products were purified with the PCRquick-spin PCR Product Purification Kit
(iNtRON Biotechnology, Gyeonggi-do, Korea) and then sequenced bi-directionally with the
second round primers using the BigDye Terminator v3.1 Cycle Sequencing kit in an ABI
PRISM 3500 Genetic Analyzer (Applied Biosystems).
HBV pre-S sequence analysis
The MEGA 5 software [14] was used to assemble the sense and anti-sense sequences of each
PCR product into a contig sequence. All the assembled sequences were aligned with respect to
HBV wild-type genotype B and genotype C reference sequences obtained from 54 HBV refer-
ence sequences retrieved from the NCBI GenBank (Accession numbers: AB073827-AB073829,
DQ995803-DQ995804, DQ089756-DQ0897804). All reference sequences were derived from
CHB patients in Hong Kong, with demographic and virologic information available in detail
[15–17]. Mutations were identified after comparison with wild-type consensus sequences of
genotype B or genotype C. Pre-S deletions were signified by the absence of one or more nucleo-
tides in the aligned sequences [13].
HBV genotypes were determined using NCBI Genotyping tool (http://www.ncbi.nlm.nih.
gov/projects/genotyping/formpage.cgi), followed by validation using phylogenetic analysis.
Detection of Positive selection codons
Datamonkey (http://www.datamonkey.org), a web-server of the HyPhy package, was used to
analyze the selection pressures acting on HBV pre-S region [18]. Selection was estimated by
comparing the ratio of synonymous and non-synonymous substitutions (dN/dS ratio, or ω) at
each codon site in HBV pre-S region. The value of ω<1, ω = 1 and ω>1 indicates negative
selection, neutral evolution, and positive selection, respectively. Codons under positive selec-
tion were detected via Single likelihood ancestor counting (SLAC) method as implemented in
HBV Pre-S Mutations Prior to HCC
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Datamonkey. The positive selection codon was defined when a p value<0.05 was obtained in
SLAC method.
Statistical analysis
Data were presented as mean ± standard deviation or median (range). Univariate analysis of
outcome variables was undertaken using the Chi-square test, Fisher’s exact test, the Student’s t-
test or spearman correlation as appropriate. Stepwise multiple logistic regression analysis was
used to determine the independent factors associated with HCC. Kaplan-Meier analysis was
used to calculate the cumulative frequencies of pre-S mutations prior to HCC. All statistical
tests were performed using SPSS 16.0 for Windows (SPSS Inc. Chicago, IL, USA). A p-value of
<0.05 was considered statistically significant.
Results
Demographics and pre-S mutations/ deletion
The demographic and virologic characteristics of patients in HCC group and HCC-free group
are depicted in Table 1. There were no statistically significant differences in age, gender and
HBeAg status between the two groups. The majority of patients were older than 50 years
(81.1%), male (79.7%) and hepatitis B e antigen (HBeAg)-negative (82.4%). All patients har-
bored either HBV genotype B or C. Genotype C was found at a higher prevalence in the HCC
group than in the HCC-free group (89.2% vs. 50.7%, p<0.001). Thirty-six of 74 (48.6%) HCC
patients and 3 of 148 (2.0%) HCC-free patients had received anti-viral therapy. Fifty-six of 74
(75.7%) HCC patients and 32 of 148 (21.6%) HCC-free patients had liver cirrhosis. The HCC
patients had higher ALT and total bilirubin levels than the HCC-free patients (p = 0.009 and
p = 0.021, respectively).
HBV pre-S deletions and point mutations that displayed a preferential distribution between
HCC and HCC-free groups are listed in Table 1. Pre-S deletions were detected in a higher pro-
portion in HCC patients (22/74, 29.7%) than in HCC-free patients (14/148, 9.5%) (p<0.001).
Higher frequencies of pre-S point mutations at 11 codons (codons 4, 27, 51, 54, 60, 62, 100,
125, 137, 166 and 167) were also observed in the HCC patients (range: 14.9–75.7%) than in the
HCC-free patients (range: 5.4–27.7%; p<0.05 for all comparisons). To explore the association
between pre-S mutations and cirrhosis, we compared the frequencies of pre-S mutations
between the 32 HCC-free patients with cirrhosis and the 116 patients without cirrhosis. There
was no significant difference in the frequencies of pre-S deletions, as well as point mutations at
the 11 codons, between two groups (all p>0.05, data not shown). We also found that the fre-
quencies of pre-S deletions and point mutations at the 11 codons between the treated and non-
treated patients were comparable (all p>0.05, data not shown).
Mapping of HCC-associated pre-S mutations
The location and size of pre-S deletions in the 14 HCC-free patients and 22 HCC patients are
depicted in Fig 1. All the pre-S deletions were in-frame deletions, with deletions ranging from 3
to 422 base pairs. Most of the pre-S deletions encompassed B- and T-cell epitopes and impor-
tant functional domains, such as pre-S1 start codon, pre-S2 start codon, hepatocyte binding
site, S promoter, CCAAT box, topology domain, nucleocapsid binding site and polymerized
human serum albumin binding site. Interestingly, more than half (21/36; 58.3%) of the samples
had pre-S deletions ended at aa140–142 of the pre-S region. Moreover, the majority of samples
(30/36; 83.3%) had pre-S deletions which encompassed the pre-S region between amino acid
(aa) 100 and aa 140, suggesting that this region may be a hot-spot region for deletions
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occurrence. In particular, of the 22 HCC patients with pre-S deletions, all but 2 patients had
pre-S deletions encompassing part or all of these regions.
The positions of the 11 pre-S point mutations that were more frequently found in HCC
patients are illustrated in Fig 1. Immune epitope mapping of these mutations showed that
point mutations located in B-cell epitope (mutations at codon 51 and 100), or T-cell epitope
(mutations at codon 54, 60 and 62), or both B- and T-cell epitopes (mutations at codon 27,
125, 137, 166 and 167). Of these 11 point mutations, only mutation at codon 4 was found out-
side the B- and T-cell epitopes. Further functional mapping of these mutations showed that
amino acid changes might impact functional domains of hepatocyte binding site, S promoter,
Table 1. Comparison of demographic and virologic characteristics for HCC patients and control HCC-
free patients.
Variable HCC (%) HCC-free (%) P
N 74 148
Age(years) 58.9±10.0 58.8±10.5 NS
<50 14 (18.9) 28 (18.9)
>50 60 (80.1) 120 (80.1)
Gender NS
Female 15 (20.3) 30 (20.3)
Male 59 (79.7) 118 (79.7)
HBeAg status NS
Positive 15 (20.3) 24 (16.2)
Negative 59 (79.7) 124 (83.8)
HBV genotype <0.001
B 8 (10.8) 73 (49.3)
C 66 (89.2) 75 (50.7)
Antiviral treated 36 (48.6) 3 (2.0) <0.001
Cirrhosis 56 (75.7) 32 (21.6) <0.001
ALT (U/L) 60.7±60.9 40.9±36.4 0.009
Total Bilirubin (μmol/L) 14.3±9.9 12.6±6.0 0.021
Pre-S deletions 22 (29.7) 14 (9.5) <0.001
W4m 11 (14.9) 8 (5.4) 0.018
DG27m 56 (75.7) 41 (27.7) <0.001
NQ51m 46 (62.2) 27 (18.2) <0.001
DA54m 45 (60.8) 37 (25) <0.001
V60m 39 (52.7) 21 (14.2) <0.001
AS62m 41 (55.4) 23 (15.5) <0.001
Q100m 32 (43.2) 11 (7.4) <0.001
TS125m 42 (56.8) 32 (21.6) <0.001
R137m 30 (40.5) 11 (7.4) <0.001
S166m 34 (45.9) 12 (8.1) <0.001
KR167m 36 (48.6) 22 (14.9) <0.001
NOTE. Variables were at the sampling time for HCC-free patients or the nearest sampling time to diagnosis
of HCC for HCC patients. Data are no. (%) of subjects or mean ± standard deviation. HCC, hepatocellular
carcinoma; NS, not signiﬁcant; ALT, Alanine Aminotransferase. To interpret the mutations listed, take
DG27m for example, D indicates the wild type amino acid in codon 27 of genotype B while G indicates the
wild type amino acid in codon 27 of genotype C, and m indicates amino acid substitution mutations.
doi:10.1371/journal.pone.0139478.t001
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heat shock protein 70 binding site, cytosolic anchorage determinant, nucleocapsid binding site,
polymerized human serum albumin binding site and transactivator.
Independent risk factors
We performed regression analysis to determine the independent effects of the factors of
HBeAg status, HBV genotype, cirrhosis status, the presence or absence of pre-S deletions, the
11 pre-S point mutations, and ALT and total bilirubin levels on the risk of HCC development.
Multiple logistic regression analysis showed that pre-S deletions (OR, 8.253; 95% CI, 2.668–
25.531; p<0.001) and 2 pre-S point mutations at codon 51 (OR, 13.917; 95% CI, 4.957–39.075;
p<0.001), codon 167 (OR, 7.880; 95% CI, 2.717–22.852; p<0.001), ALT level (OR, 1.014; 95%
CI, 1.002–1.025; p = 0.018) and cirrhosis (OR, 0.058; 95% CI, 0.022–0.157; p<0.001) were
independent risk factors to the development of HCC (Table 2). HBeAg status, HBV genotype,
total bilirubin level, and the rest of the 9 pre-S point mutations were not independent factors
associated with HCC development (all p>0.05).
Positive selection codons detection
Positive selection codons that computed by SLAC method are depicted in Fig 2. We identified
5 amino acid sites (codon 27, 35, 54, 137 and 167) which were under positive selection pressure
in genotype C sequences, while no positive selection codon was detected in genotype B
sequences. Immune epitope mapping of these mutations suggested that all of these amino acid
substitutions were located in B- or/and T-cell epitopes. In particular, frequencies of amino acid
substitutions at codon 27, 54, 137 and 167 were significantly higher in HCC group than HCC-
free group (p<0.05 for all comparisons).
Pre-S mutations longitudinal study
Fifty-six HCC patients and 47 HCC-free patients had serial serum samples available for longi-
tudinal analysis. The changes in frequencies of pre-S deletions and the 11 pre-S point muta-
tions over time in these 103 patients were depicted in Table 3. In the 56 HCC patients, pre-S
deletions were detected in 25%, 25%, 48.6%, and 42.9% of HCC patients at 1–3 years, 4–6
years, 7–9 years, and10 years prior to HCC development, respectively. In the HCC-free
group, the frequencies of pre-S deletions at the 4 corresponding time points were lower (8.5%,
7.9%, 8.8%, and 17.6%, respectively; with p values of 0.037, 0.05,<0.001, and 0.161, respec-
tively). As depicted in Fig 3, of the 14 HCC patients detected with pre-S deletions at 1–3 years
before HCC, pre-S deletions were also detected in 7 patients at 4–6 years earlier, in 8 patients at
7–9 years earlier, and in 4 patients at10 years before HCC. However, in 12 HCC patients,
pre-S deletions were detected only at earlier time points (4–6 years, 7–9 years, or10 years),
but not detected at 1–3 years prior to HCC. Taken together, a significantly higher cumulative
Table 2. Independent risk factors associated with HCC development.
OR 95% CI P value
Pre-S deletions 8.253 2.668–25.531 <0.001
NQ51m 13.917 4.957–39.075 <0.001
KR167m 7.880 2.717–22.852 <0.001
ALT 1.014 1.002–1.025 0.018
Cirrhosis 0.058 0.022–0.157 <0.001
Note. OR: odds ratios of HCC-related factors; 95% CI, 95% conﬁdence intervals.
doi:10.1371/journal.pone.0139478.t002
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frequencies of pre-S deletion were observed in the HCC group than HCC-free group (16.1% vs.
6.4% at10 years, 30.4% vs. 8.5% at 7–9 years, 41.1% vs. 10.6% at 4–6 years, and 46.4% vs.
10.6% at 1–3 years prior to HCC, respectively, p<0.001).
Next, we focused on the 11 pre-S point mutations that were identified more frequently in
HCC patients in our case-control study. Of these 11 pre-S mutations, 10 (except codon 4) were
also found at higher frequencies in the HCC group than the HCC-free group at 1–3 years prior
to HCC development in our longitudinal cohort. All these 10 pre-S mutations existed10
years before HCC. Among these 10 mutations, the number of mutated codons with differential
distribution between the HCC and HCC-free patients increased with time prior to HCC: a sig-
nificantly higher frequency of mutations was detected in the HCC patients in 2/10 codons at
10 years, in 9/10 codons at 7–9 years, in 10/10 codons at 4–6 years, and 10/10 codons at 1–3
years prior to HCC.
The accumulation of HCC-associated pre-S point mutations were illustrated in Fig 4A. The
number of pre-S point mutations in the HCC patients increased over time preceding HCC
development, and correlated positively with the time to HCC diagnosis (spearman correlation
coefficient = 0.220; p = 0.005). On the other hand, the bubble plot of HCC-free group showed
the prevalence of pre-S point mutations was relatively low at 4 matched time points (Fig 4B).
Although the number of pre-S point mutations tended to increase over time, there was no cor-
relation between the time and number of mutations in the HCC-free group (spearman correla-
tion coefficient = 0.073; p = 0.398).
Fig 2. The positive selection codons detected in genotype C sequences. Prevalence of mutations at positive selected sites of genotype C sequences in
HCC and HCC-free group.
doi:10.1371/journal.pone.0139478.g002
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Discussion
The present study is the first to investigate the prevalence and changes of pre-S mutations with
a long term (as long as 10 years) follow-up prior to HCC development. We identified pre-S
deletions and 11 pre-S point mutations that were more frequently detected in HCC patients
with a case-control approach. Using a longitudinal approach, we further showed that these
Table 3. Pre-S deletions/point mutations at time points assessed prior to HCC development.
Years prior to HCC 10 years 7–9 years 4–6 years 1–3 years
Pre-S deletions HCC 9/21 (42.9%) 17/35 (48.6%) 13/52 (25%) 14/56 (25%)
HCC-free 3/17 (17.6%) 3/34 (8.8%) 3/38 (7.9%) 4/47 (8.5%)
P value 0.161 <0.001 0.05 0.037
W4m HCC 0/21 (0%) 0/35 (0%) 5/52 (9.6%) 6/56 (10.7%)
HCC-free 0/17 (0%) 2/34 (5.9%) 5/38 (13.2%) 4/47 (8.5%)
P value 1 0.239 0.737 0.752
DG27m HCC 12/21 (57.1%) 22/35 (62.9%) 36/52 (69.2%) 43/56 (76.8%)
HCC-free 6/17 (35.3%) 7/34 (20.6%) 7/38 (18.4%) 11/47 (23.4%)
P value 0.180 <0.001 <0.001 <0.001
NQ51m HCC 9/21 (42.9%) 17/35 (48.6%) 35/52 (67.3%) 35/56 (62.5%)
HCC-free 5/17 (29.4%) 8/34 (23.5%) 11/38 (28.9%) 9/47 (19.1%)
P value 0.393 0.030 <0.001 <0.001
DA54m HCC 10/21 (47.6%) 15/35 (42.9%) 32/52 (61.5%) 36/56 (64.3%)
HCC-free 3/17 (17.6%) 6/34 (17.6%) 10/38 (26.3%) 14/47 (29.8%)
P value 0.086 0.023 0.001 <0.001
V60m HCC 9/21 (42.9%) 14/35 (40%) 34/52 (65.4%) 34/56 (60.7%)
HCC-free 3/17 (17.6%) 4/34 (11.8%) 8/38 (21.1%) 8/47(17.0%)
P value 0.161 0.013 <0.001 <0.001
AS62m HCC 8/21 (38.1%) 15/35 (42.9%) 30/52 (57.7%) 34/56 (60.7%)
HCC-free 3/17 (17.6%) 5/34 (14.7%) 8/38 (21.1%)) 9/47 (19.1%)
P value 0.282 0.010 0.001 <0.001
Q100m HCC 7/21 (33.3%) 11/35 (31.4%) 27/52 (51.9%) 30/56 (53.6%)
HCC-free 0/17 (0%) 1/34 (2.9%) 3/38 (7.9%) 4/47 (8.5%)
P value 0.011 0.003 0.001 <0.001
TS125m HCC 10/21 (47.6%) 17/35 (48.6%) 35/52 (67.3%) 37/56 (66.1%)
HCC-free 4/17 (23.5%) 7/34 (20.6%) 12/38 (31.6%) 13/47 (27.7%)
P value 0.181 0.015 0.001 <0.001
R137m HCC 6/21 (28.6%) 10/35(28.6%) 28/52 (53.8%) 27/56 (48.2%)
HCC-free 0/17 (0%) 1/34 (2.9%) 3/38 (7.9%) 3/47 (6.4%)
P value 0.024 0.006 <0.001 <0.001
S166m HCC 6/21 (28.6%) 13/35 (37.1%) 29/52 (55.8%) 32/56 (57.1%)
HCC-free 1/17 (5.9%) 3/34 (8.8%) 5/38 (13.2%) 6/47 (12.8%)
P value 0.104 0.009 <0.001 <0.001
KR167m HCC 5/21 (23.8%) 9/35 (25.7%) 26/52 (50%) 32/56 (57.1%)
HCC-free 2/17 (11.8%) 5/34 (14.7%) 7/38 (18.4%) 9/47 (19.1%)
P value 0.427 0.256 0.002 <0.001
Note. To interpret the mutations listed, take DG27m for example, D indicates the wild type amino acid in codon 27 of genotype B while G indicates the
wild type amino acid in codon 27 of genotype C, and m indicates amino acid substitution mutations. Data are no./no.(%) of subjects detected with
mutations/ total subjects unless otherwise speciﬁed.
doi:10.1371/journal.pone.0139478.t003
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pre-S deletions/mutations already existed at least 10 years before the diagnosis of HCC and
were highly prevalent prior to HCC diagnosis. Prior to HCC development, an increase occur-
rence of pre-S point mutations over time was also observed whereas this phenomenon was not
observed in the controls without development of HCC.
Our finding that pre-S deletion was an independent risk factor for HCC development was
consistent with most previous studies [6, 11, 12]. The hepatocarcinogenic role of pre-S dele-
tions has been suggested by previous studies. Both pre-S1 and pre-S2 deletions can cause accu-
mulation of LHBs proteins and viral particles in the endoplasmic reticulum (ER), and
subsequently induce ER stress and oxidative DNA damage of HBV-infected hepatocytes,
which may involved in the hepatocarcinogenesis [19]. In addition, LHBs and truncated middle
Fig 3. Longitudinal observation of pre-S deletions over time prior to HCC development. Each
sequence is depicted as a block and its location relative to the timeline indicates the time points prior to
diagnosis of HCC. Empty blocks represent sequences without pre-S deletions; whereas black blocks
represent sequences with pre-S deletions. The patient identifier numbers are listed at the right.
doi:10.1371/journal.pone.0139478.g003
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surface protein have been recognized to be transcriptional activators which may initiate the
Ras/Raf-1/ERK signaling, and hence be another oncogenic mechanism [20]. A recent study
also demonstrates an enhanced expression of VEGF-A and activation of Akt/mTOR signaling
in ground glass hepatocytes harboring pre-S deletion mutants, thus providing another poten-
tial mechanism for tumorigenesis [21].
Unlike pre-S deletions, pre-S point mutations in relation to HCC have been not well charac-
terized. In the present study, we identified 11 pre-S point mutations that were highly associated
with HCC development. Consistent with our study, Chen et al. [11] also found that point
mutation at codon 4 in pre-S region is associated with HCC by a case-control study. In addi-
tion, Yin et al. [13] also demonstrated higher frequencies of point mutations at codon 4, 60 and
125 in the pre-S region in HCC patients. The impact of various HBV pre-S point mutations on
HCC development remains unclear. As observed in Fig 1, functional mapping of pre-S muta-
tions suggested that those point mutations frequently occurred in the B- and T-cell epitopes
and functional domains. Point mutations in the S promoter and the CCAAT binding factors
could lead to decreased synthesis of surface protein, resulting in intracellular retention of enve-
lope proteins and ER stress, thus possibly inducing HCC carcinogenesis [22–24]. To fully
explore the relationship between HBV pre-S mutations and HCC development, further eluci-
dation of molecular mechanism focusing on hepatocyte transformation through construction
of liver cell lines expressing these pre-S mutations are needed.
In our study, of the 5 codons under positive selection, the frequencies of point mutations at
codon 27, 54, 137 and 167 were significantly higher in the HCC group than HCC-free group.
All these codons were within B- and T- cell epitopes, while alternations in these immune target
sites could lead to escape from immune surveillance and result in persistent infection [24]. It is
likely that these point mutations were positively selected by immune pressure during HCC
development. This is supported by our longitudinal results which showed accumulation of
these mutations over time before HCC development. Thus, our results suggested that the posi-
tive selection might be responsible for the generation of HCC-associated point mutations.
To our best knowledge, up to now, there are only limited longitudinal studies of pre-S muta-
tions in relation to the development of HCC. Qu et al. [25] showed that complex HBV
Fig 4. Changes of HBV pre-S point mutations numbers prior to HCC development. Bubble plot of
cumulative number of HBV pre-S point mutations associated with HCC at 4 time points in HCC group (A) and
HCC-free group (B). Time points 1–4 represent time points of more than10 years, 7–9 years, 4–6 years and
1–3 years before HCC diagnosis, respectively. The size of the circles corresponds to the number of patients
at each given time point detected with each given number of point mutation.
doi:10.1371/journal.pone.0139478.g004
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mutations (pre-S deletions, T1762/A1764, and T1766 and/or A1768 mutants) were gradually
combined during the development of HCC. Our previous study [12] also reported the emer-
gence of de novo pre-S deletions before the development of HCC. However, the 2 above-men-
tioned studies were limited by the small number of HCC patients and the short follow-up time.
In the current study, we recruited a large number of patients with longer follow-up duration
and found that a high prevalence of pre-S deletions and point mutations was detected at up to
10 years prior to HCC development. Although the frequency of pre-S deletions seemed to pro-
gressively decrease prior to HCC, this might be due to the markedly increasing number of
available serum samples from 10 years before HCC to the time near HCC diagnosis. To verify
this, we performed a Kaplan-Meier analysis and found that there was a significantly increased
cumulative frequency of pre-S deletions prior to HCC, which strongly supported the carcinoge-
netic role of pre-S deletions. In addition, we identified that there was an increasing trend of the
number of pre-S point mutations over time before the development of HCC. Taken together,
our results suggest that, in addition to pre-S deletion, these pre-S mutations might also be
involved in the pathogenesis of HCC. In addition, early detection of pre-S deletions and point
mutations as early as 10 years prior to HCCmay potentially permit the formulation of a predic-
tive HCC risk score for CHB patients.
The present study has several limitations. First, it is not possible to determine the exact time
of the emergence of HCC. In the current study, we used the time of clinical diagnosis of HCC.
Depending on the frequency of follow-up, the exact time of the emergence of HCC may differ.
Nevertheless, like all other clinical studies, this may be the best possible estimation. Secondly,
data for HBV DNA, a known risk factor for HCC prediction, were not available. Finally, we
determined pre-S mutations via direct sequencing method, which could not detect mutations
that existed as minority below 20% of the viral quasi-species [26]. In this study, the discontinu-
ous observation of pre-S deletions during HCC development might be a result of HBV variants
harboring pre-S deletions evolving as minority of quasispecies and were missed by direct
sequencing. Thus, the prevalence of pre-S mutations might be underestimated, and further
studies using more sensitive sequencing techniques are encouraged.
In conclusion, our current study identified a high prevalence of pre-S deletions and point
mutations prior to HCC development. In particular, pre-S deletions, and point mutations at
pre-S codons 51 and 167 were independent factors associated with HCC development. Pre-S
mutations existed at least 10 years before the diagnosis of HCC, and the number of mutations
increased over time. Our findings suggested the carcinogenic role of pre-S mutations and their
potential application in HCC risk prediction. The effect of individual pre-S mutations on HCC
development warrants further studies.
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